These are the numbers as far as i know. From the ASX release dated 19 March 2007
"17 patients received 600 mg doses of ATC, 16 received 800 mg doses of ATC and the control group of 14 patients were treated with 3TC."
Don't confuse this with the following
"ATC continues to be very well tolerated, with some patients having received more than 12 months treatment to date. Currently there are 14 patients in the open label section of the Phase IIb trial and 6 patients have elected to enter into an extension study (where they continue to be treated with ATC), having completed the full 48 weeks of the study."
and don't forget ATC has been touted as becoming "the most effective and well tolerated NRTI for treatment of drug-resistant HIV”
None of this is new and the market is waiting for the next batch of results or interest from a major or ??
AVX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held